Patent ID: 8481598

Claim:
A method for treating major depressive disorder in a patient in need thereof, comprising administering to the patient about 120 mg/day of levomilnacipran or a pharmaceutically acceptable salt thereof in one or more sustained release oral dosage forms, wherein the administering step provides a therapeutic blood plasma level of levomilnacipran or pharmaceutically acceptable salt thereof over approximately a twenty-four hour period to treat major depressive disorder in the patient, and wherein the administering step provides an average maximum plasma concentration (C max ) between about 50 ng/mL and about 350 ng/mL of levomilnacipran or pharmaceutically acceptable salt thereof, an AUC 0-∞ between about 1000 ng·hr/mL and about 9000 ng·hr/mL and a T max of at least 3 hours to the patient.